The TRANQUILITY 2 Trial: A Phase 3 Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease

NCT05062330 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

361

Enrollment

INDUSTRY

Sponsor class

Conditions

Dry Eye

Interventions

DRUG: Reproxalap Ophthalmic Solution (0.25%)
DRUG: Vehicle Ophthalmic Solution

Sponsor

Aldeyra Therapeutics, Inc.